New report calls on governments to implement national policies on hepatitis C

25 June 2014
janssen-logo-big

A report published by The Economist Intelligence Unit (EIU) has revealed that many countries around the world have been slow to respond with national policies on hepatitis C despite recent government pledges to fight the disease.

The report, Tackling hepatitis C: Moving towards an integrated policy approach, states that even though incremental progress has been made ‘concrete initiatives remain thin on the ground’ because of limited resources, data and information about the impact of hepatitis C. The report finds that, despite growing awareness of the disease, epidemiological data remains scarce. This improved awareness underscores the need for a co-ordinated response. However, global variations in prevalence of and approaches to addressing hepatitis C still persist.

The hepatitis C virus remains the leading cause of liver cancer, liver disease and liver transplantation placing a huge burden on patient’s lives and healthcare systems. Non-government organizations (NGOs) and patient groups are leading the way in raising awareness of hepatitis C and calling for rapid responses from governments.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical